- Home
- Publications
- Publication Search
- Publication Details
Title
Therapeutic Approaches in Lysosomal Storage Diseases
Authors
Keywords
-
Journal
Biomolecules
Volume 11, Issue 12, Pages 1775
Publisher
MDPI AG
Online
2021-11-29
DOI
10.3390/biom11121775
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Lentivirus-mediated gene therapy for Fabry disease
- (2021) Aneal Khan et al. Nature Communications
- Impact of Long-Term Enzyme Replacement Therapy on Glucosylsphingosine (Lyso-Gb1) Values in Patients with Type 1 Gaucher Disease: Statistical Models for Comparing Three Enzymatic Formulations
- (2021) Tama Dinur et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Lentiviral hematopoietic stem and progenitor cell gene therapy (HSPC-GT) for metachromatic leukodystrophy (MLD): Clinical outcomes from 33 patients
- (2020) Francesca Fumagalli et al. MOLECULAR GENETICS AND METABOLISM
- First-in-human study of a liver-directed AAV gene therapy (FLT190) in Fabry disease
- (2020) Derralynn A. Hughes et al. MOLECULAR GENETICS AND METABOLISM
- Krabbe disease successfully treated via monotherapy of intrathecal gene therapy
- (2020) Allison M. Bradbury et al. JOURNAL OF CLINICAL INVESTIGATION
- Safety of intrathecal delivery of recombinant human arylsulfatase A in children with metachromatic leukodystrophy: Results from a phase 1/2 clinical trial
- (2020) Christine í Dali et al. MOLECULAR GENETICS AND METABOLISM
- Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Oral Venglustat in Healthy Volunteers
- (2020) M. Judith Peterschmitt et al. Clinical Pharmacology in Drug Development
- Systemic treatment of Fabry disease using a novel AAV9 vector expressing α-Galactosidase A
- (2020) Maria Grazia Biferi et al. Molecular Therapy-Methods & Clinical Development
- AAV2/6 Gene Therapy in a Murine Model of Fabry Disease Results in Supraphysiological Enzyme Activity and Effective Substrate Reduction
- (2020) Makiko Yasuda et al. Molecular Therapy-Methods & Clinical Development
- Nanotechnology‐based approaches for treating lysosomal storage disorders, a focus on Fabry disease
- (2020) Ibane Abasolo et al. Wiley Interdisciplinary Reviews-Nanomedicine and Nanobiotechnology
- In Vitro and In Vivo Amenability to Migalastat in Fabry Disease
- (2020) Malte Lenders et al. Molecular Therapy-Methods & Clinical Development
- Long-term neurodevelopmental outcomes of hematopoietic stem cell transplantation for late-infantile Krabbe disease
- (2020) Isabel C. Yoon et al. BLOOD
- Adeno-associated virus vector as a platform for gene therapy delivery
- (2019) Dan Wang et al. NATURE REVIEWS DRUG DISCOVERY
- FACTs Fabry gene therapy clinical trial: Two-year data
- (2019) Jeffrey A. Medin et al. MOLECULAR GENETICS AND METABOLISM
- Pegunigalsidase alfa, a novel PEGylated enzyme replacement therapy for Fabry disease, provides sustained plasma concentrations and favorable pharmacodynamics: a 1-year Phase 1/2 clinical trial
- (2019) Raphael Schiffmann et al. JOURNAL OF INHERITED METABOLIC DISEASE
- Efficacy of the pharmacologic chaperone migalastat in a subset of male patients with the classic phenotype of Fabry disease and migalastat-amenable variants: data from the phase 3 randomized, multicenter, double-blind clinical trial and extension study
- (2019) Dominique P. Germain et al. GENETICS IN MEDICINE
- Safety of switching to Migalastat from enzyme replacement therapy in Fabry disease: Experience from the Phase 3 ATTRACT study
- (2019) Derralynn A. Hughes et al. AMERICAN JOURNAL OF MEDICAL GENETICS PART A
- The glycosylation design space for recombinant lysosomal replacement enzymes produced in CHO cells
- (2019) Weihua Tian et al. Nature Communications
- Intracerebroventricular enzyme replacement therapy with Beta-Galactosidase reverses brain pathologies due to GM1 gangliosidosis in mice
- (2019) Joseph C Chen et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- AAVrh10 Gene Therapy Ameliorates Central and Peripheral Nervous System Disease in Canine Globoid Cell Leukodystrophy (Krabbe Disease)
- (2018) Allison M. Bradbury et al. HUMAN GENE THERAPY
- Agalsidase alfa versus agalsidase beta for the treatment of Fabry disease: an international cohort study
- (2018) Maarten Arends et al. JOURNAL OF MEDICAL GENETICS
- CRISPR-Cas guides the future of genetic engineering
- (2018) Gavin J. Knott et al. SCIENCE
- Iduronate-2-Sulfatase with Anti-human Transferrin Receptor Antibody for Neuropathic Mucopolysaccharidosis II: A Phase 1/2 Trial
- (2018) Torayuki Okuyama et al. MOLECULAR THERAPY
- Safety, tolerability, pharmacokinetics, pharmacodynamics, and exploratory efficacy of the novel enzyme replacement therapy avalglucosidase alfa (neoGAA) in treatment-naïve and alglucosidase alfa-treated patients with late-onset Pompe disease: a phase 1, open-label, multicenter, multinational, ascending dose study
- (2018) Loren D.M. Pena et al. NEUROMUSCULAR DISORDERS
- Lucerastat, an iminosugar with potential as substrate reduction therapy for glycolipid storage disorders: safety, tolerability, and pharmacokinetics in healthy subjects
- (2017) N. Guérard et al. Orphanet Journal of Rare Diseases
- Rescue of Pompe disease in mice by AAV-mediated liver delivery of secretable acid α-glucosidase
- (2017) Francesco Puzzo et al. Science Translational Medicine
- Development of idursulfase therapy for mucopolysaccharidosis type II (Hunter syndrome): the past, the present and the future
- (2017) David Whiteman et al. Drug Design Development and Therapy
- Gene editing for cell engineering: trends and applications
- (2016) Sanjeev K. Gupta et al. CRITICAL REVIEWS IN BIOTECHNOLOGY
- Survival and long-term outcomes in late-onset Pompe disease following alglucosidase alfa treatment: a systematic review and meta-analysis
- (2016) Benedikt Schoser et al. JOURNAL OF NEUROLOGY
- Lysosomal Storage Diseases: From Pathophysiology to Therapy
- (2015) Giancarlo Parenti et al. Annual Review of Medicine
- In vivo genome editing of the albumin locus as a platform for protein replacement therapy
- (2015) R. Sharma et al. BLOOD
- Liver-targeted gene therapy: Approaches and challenges
- (2015) Rajagopal N. Aravalli et al. LIVER TRANSPLANTATION
- ENCORE, a randomized, controlled, open-label non-inferiority study comparing eliglustat to imiglucerase in Gaucher disease type 1 patients stabilized on enzyme replacement therapy: 24-month results
- (2015) Timothy M. Cox et al. MOLECULAR GENETICS AND METABOLISM
- Characterization of a chemically modified plant cell culture expressed human α-Galactosidase-A enzyme for treatment of Fabry disease
- (2015) Tali Kizhner et al. MOLECULAR GENETICS AND METABOLISM
- Pharmacological Chaperone Therapy: Preclinical Development, Clinical Translation, and Prospects for the Treatment of Lysosomal Storage Disorders
- (2015) Giancarlo Parenti et al. MOLECULAR THERAPY
- Oral Migalastat HCl Leads to Greater Systemic Exposure and Tissue Levels of Active α-Galactosidase A in Fabry Patients when Co-Administered with Infused Agalsidase
- (2015) David G. Warnock et al. PLoS One
- Eliglustat tartrate
- (2014) J.A. Shayman DRUGS OF THE FUTURE
- The Phytoestrogen Genistein Modulates Lysosomal Metabolism and Transcription Factor EB (TFEB) Activation
- (2014) Marta Moskot et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- The Pharmacological Chaperone AT2220 Increases the Specific Activity and Lysosomal Delivery of Mutant Acid Alpha-Glucosidase, and Promotes Glycogen Reduction in a Transgenic Mouse Model of Pompe Disease
- (2014) Richie Khanna et al. PLoS One
- Globotriaosylceramide Induces Endothelial Dysfunction in Fabry Disease
- (2013) Kimio Satoh ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- TFEB regulates lysosomal proteostasis
- (2013) Wensi Song et al. HUMAN MOLECULAR GENETICS
- Signals from the lysosome: a control centre for cellular clearance and energy metabolism
- (2013) Carmine Settembre et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Algorithm for the Early Diagnosis and Treatment of Patients with Cross Reactive Immunologic Material-Negative Classic Infantile Pompe Disease: A Step towards Improving the Efficacy of ERT
- (2013) Suhrad G. Banugaria et al. PLoS One
- Lentiviral Hematopoietic Stem Cell Gene Therapy Benefits Metachromatic Leukodystrophy
- (2013) A. Biffi et al. SCIENCE
- Autophagy in lysosomal storage disorders
- (2012) Andrew P. Lieberman et al. Autophagy
- A lysosome-to-nucleus signalling mechanism senses and regulates the lysosome via mTOR and TFEB
- (2012) Carmine Settembre et al. EMBO JOURNAL
- New strategies for the treatment of lysosomal storage diseases (Review)
- (2012) GIANCARLO PARENTI et al. INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE
- Miglustat-induced intestinal carbohydrate malabsorption is due to the inhibition of α-glucosidases, but not β-galactosidases
- (2012) Mahdi Amiri et al. JOURNAL OF INHERITED METABOLIC DISEASE
- Long-Term Effect of Antibodies against Infused Alpha-Galactosidase A in Fabry Disease on Plasma and Urinary (lyso)Gb3 Reduction and Treatment Outcome
- (2012) Saskia M. Rombach et al. PLoS One
- Enzyme replacement therapy for lysosomal storage diseases
- (2011) Robin H. Lachmann CURRENT OPINION IN PEDIATRICS
- Transcriptional Activation of Lysosomal Exocytosis Promotes Cellular Clearance
- (2011) Diego L. Medina et al. DEVELOPMENTAL CELL
- The impact of antibodies on clinical outcomes in diseases treated with therapeutic protein: Lessons learned from infantile Pompe disease
- (2011) Suhrad G. Banugaria et al. GENETICS IN MEDICINE
- Production of active human glucocerebrosidase in seeds of Arabidopsis thaliana complex-glycan-deficient (cgl) plants
- (2011) Xu He et al. GLYCOBIOLOGY
- Intracerebroventricular enzyme infusion corrects central nervous system pathology and dysfunction in a mouse model of metachromatic leukodystrophy
- (2011) S. Stroobants et al. HUMAN MOLECULAR GENETICS
- Autophagy in skeletal muscle: implications for Pompe disease
- (2011) L. Shea et al. INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS
- Reversal of Lysosomal Storage in Brain of Adult MPS-I Mice with Intravenous Trojan Horse-Iduronidase Fusion Protein
- (2011) Ruben J. Boado et al. MOLECULAR PHARMACEUTICS
- Therapy for the mucopolysaccharidoses
- (2011) V. Valayannopoulos et al. RHEUMATOLOGY
- mTORC1 Senses Lysosomal Amino Acids Through an Inside-Out Mechanism That Requires the Vacuolar H+-ATPase
- (2011) R. Zoncu et al. SCIENCE
- HSP70 and lysosomal storage disorders: novel therapeutic opportunities
- (2010) Nikolaj H.T. Petersen et al. BIOCHEMICAL SOCIETY TRANSACTIONS
- Ragulator-Rag Complex Targets mTORC1 to the Lysosomal Surface and Is Necessary for Its Activation by Amino Acids
- (2010) Yasemin Sancak et al. CELL
- Lysosomal Storage Disease: Revealing Lysosomal Function and Physiology
- (2010) Emma J. Parkinson-Lawrence et al. PHYSIOLOGY
- Glycan Engineering and Production of ‘Humanized’ Glycoprotein in Yeast Cells
- (2009) Yasunori Chiba et al. BIOLOGICAL & PHARMACEUTICAL BULLETIN
- The pharmacological chaperone 1-deoxynojirimycin increases the activity and lysosomal trafficking of multiple mutant forms of acid alpha-glucosidase
- (2009) John J. Flanagan et al. HUMAN MUTATION
- Catalytic Mechanism of Human α-Galactosidase
- (2009) Abigail I. Guce et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Long-Term Miglustat Therapy in Children With Niemann-Pick Disease Type C
- (2009) Marc C. Patterson et al. JOURNAL OF CHILD NEUROLOGY
- AAV9: a potential blood-brain barrier buster
- (2009) Fredric P Manfredsson et al. MOLECULAR THERAPY
- A Gene Network Regulating Lysosomal Biogenesis and Function
- (2009) Marco Sardiello et al. SCIENCE
- Transplant Outcomes in Leukodystrophies
- (2009) Paul J. Orchard et al. SEMINARS IN HEMATOLOGY
- Isofagomine increases lysosomal delivery of exogenous glucocerebrosidase
- (2008) Jin-Song Shen et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Sorting of lysosomal proteins
- (2008) Thomas Braulke et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH
- Chemical and Biological Approaches Synergize to Ameliorate Protein-Folding Diseases
- (2008) Ting-Wei Mu et al. CELL
- Niemann-Pick disease type C1 is a sphingosine storage disease that causes deregulation of lysosomal calcium
- (2008) Emyr Lloyd-Evans et al. NATURE MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started